We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.21 | -0.50% | 41.40 | 42.03 | 41.42 | 41.75 | 3,672,349 | 01:00:00 |
From May 2019 to May 2024
GlaxoSmithKline PLC posted a loss in the second quarter, reflecting a £ 1.8 billion ($2.36 billion) write-down related to the increased value of liabilities following the sharp drop in the value of the pound triggered by Britain's vote to leave the European Union.
The pharmaceutical giant posted a net loss of £ 435 million for the three months to June 30, compared with £ 149 million net profit reported a year earlier.
Core operating profit, a measure that strips out one-time losses and gains, increased 36% to £ 1.8 billion, as revenue climbed 11% to £ 6.5 billion, beating analyst forecasts of £ 6.3 billion.
Glaxo reports in pounds but makes most of its revenue outside the U.K., meaning its reported revenue benefited from the sharp drop in the value of the pound following the Brexit vote, a currency move that also increased the value of Glaxo's liabilities. Adjusting for currency, core operating profit climbed 15% and revenue rose 4%.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
July 27, 2016 08:05 ET (12:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
